347 related articles for article (PubMed ID: 24158110)
21. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
Carrillo JA; Lai A; Nghiemphu PL; Kim HJ; Phillips HS; Kharbanda S; Moftakhar P; Lalaezari S; Yong W; Ellingson BM; Cloughesy TF; Pope WB
AJNR Am J Neuroradiol; 2012 Aug; 33(7):1349-55. PubMed ID: 22322613
[TBL] [Abstract][Full Text] [Related]
22. [Analyses of IDH1 mutation and MGMT promoter methylation status for 5 cases of long-term survivors with glioblastoma].
Kamoshima Y; Motegi H; Terasaka S; Kobayashi H; Yamaguchi S; Murata J; Tanaka S; Houkin K
No Shinkei Geka; 2012 Feb; 40(2):129-35. PubMed ID: 22281465
[TBL] [Abstract][Full Text] [Related]
23. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
24. Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO).
Leibetseder A; Ackerl M; Flechl B; Wöhrer A; Widhalm G; Dieckmann K; Kreinecker SS; Pichler J; Hainfellner J; Preusser M; Marosi C
Neuro Oncol; 2013 Jan; 15(1):112-21. PubMed ID: 23223340
[TBL] [Abstract][Full Text] [Related]
25. IDH1 mutation of gliomas with long-term survival analysis.
Myung JK; Cho HJ; Park CK; Kim SK; Phi JH; Park SH
Oncol Rep; 2012 Nov; 28(5):1639-44. PubMed ID: 22922798
[TBL] [Abstract][Full Text] [Related]
26. Association of loss of heterozygosity with shorter survival in primary glioblastoma patients.
Jesionek-Kupnicka D; Szybka M; Potemski P; Kulczycka-Wojdala D; Jaskólski D; Bieńkowski M; Skowroński W; Papierz W; Kordek R; Zawlik I
Pol J Pathol; 2013 Dec; 64(4):268-75. PubMed ID: 24375041
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.
Lötsch D; Ghanim B; Laaber M; Wurm G; Weis S; Lenz S; Webersinke G; Pichler J; Berger W; Spiegl-Kreinecker S
Neuro Oncol; 2013 Apr; 15(4):423-32. PubMed ID: 23393205
[TBL] [Abstract][Full Text] [Related]
28. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
29. Molecular characteristics of glioblastoma with 1p/19q co-deletion.
Mizoguchi M; Yoshimoto K; Ma X; Guan Y; Hata N; Amano T; Nakamizo A; Suzuki SO; Iwaki T; Sasaki T
Brain Tumor Pathol; 2012 Jul; 29(3):148-53. PubMed ID: 22736234
[TBL] [Abstract][Full Text] [Related]
30. A practical review of prognostic correlations of molecular biomarkers in glioblastoma.
Karsy M; Neil JA; Guan J; Mahan MA; Colman H; Jensen RL
Neurosurg Focus; 2015 Mar; 38(3):E4. PubMed ID: 25727226
[TBL] [Abstract][Full Text] [Related]
31. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival.
Leu S; von Felten S; Frank S; Vassella E; Vajtai I; Taylor E; Schulz M; Hutter G; Hench J; Schucht P; Boulay JL; Mariani L
Neuro Oncol; 2013 Apr; 15(4):469-79. PubMed ID: 23408861
[TBL] [Abstract][Full Text] [Related]
32. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
[TBL] [Abstract][Full Text] [Related]
33. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.
Figarella-Branger D; Mokhtari K; Colin C; Uro-Coste E; Jouvet A; Dehais C; Carpentier C; Villa C; Maurage CA; Eimer S; Polivka M; Vignaud JM; Laquerriere A; Sevestre H; Lechapt-Zalcman E; Quintin-Roué I; Aubriot-Lorton MH; Diebold MD; Viennet G; Adam C; Loussouarn D; Michalak S; Rigau V; Heitzmann A; Vandenbos F; Forest F; Chiforeanu D; Tortel MC; Labrousse F; Chenard MP; Nguyen AT; Varlet P; Kemeny JL; Levillain PM; Cazals-Hatem D; Richard P; Delattre JY;
Brain Pathol; 2015 Jul; 25(4):418-28. PubMed ID: 25407774
[TBL] [Abstract][Full Text] [Related]
35. Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma.
Kraus TF; Kolck G; Greiner A; Schierl K; Guibourt V; Kretzschmar HA
Tumour Biol; 2015 Nov; 36(11):8439-46. PubMed ID: 26022161
[TBL] [Abstract][Full Text] [Related]
36. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
[TBL] [Abstract][Full Text] [Related]
38. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
[TBL] [Abstract][Full Text] [Related]
39. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.
Molenaar RJ; Verbaan D; Lamba S; Zanon C; Jeuken JW; Boots-Sprenger SH; Wesseling P; Hulsebos TJ; Troost D; van Tilborg AA; Leenstra S; Vandertop WP; Bardelli A; van Noorden CJ; Bleeker FE
Neuro Oncol; 2014 Sep; 16(9):1263-73. PubMed ID: 24510240
[TBL] [Abstract][Full Text] [Related]
40. MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.
Lei L; Jiang Z; Zhang G; Cheng Q; Lu H
World J Surg Oncol; 2018 Jun; 16(1):110. PubMed ID: 29914531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
